Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.02 | N/A | +5.05% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.05% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for the upcoming periods.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report shows that Johnson & Johnson managed to beat expectations on EPS, indicating strong profitability. However, without revenue figures or stock reaction data, it's difficult to gauge overall market sentiment. The lack of guidance may leave investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ERICSSON B ADR
Jan 25, 2010